From cancer to cardiovascular disease: how a UCL academic’s lab to market journey is giving hope to millions.
Inhibiting LRG1 is a new frontier for health, according to Professor John Greenwood, who joins us for an afternoon chat to discuss his pioneering efforts giving hope to those affected by cancer, chronic kidney, lung and ocular disease.
Learn how John’s work with UCLB to form Senya Therapeutics is targeting real world impact.
This talk is brought to you by UCLB BioPharm ‘Lab to Market’ series, a networking event for academics to informally discuss topics relevant to research commercialisation with UCLB .
These sessions are not intended for PhD students and are open to academics and research staff/fellows only.
Register